Autonomix Medical, Inc. (NASDAQ:AMIX) Shares Shorted: Short Interest Down 56.3% in September

Autonomix Medical, Inc. (NASDAQ:AMIX) was the recipient of a significant drop in short interest during the month of September. As of September 30th, there was short interest totaling 26,830 shares, a drop of 56.3% from the September 15th total of 61,425 shares. Based on an average daily trading volume, of 114,154 shares, the short-interest ratio is presently 0.2 days. Currently, 2.9% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AMIX shares. Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Wall Street Zen raised shares of Autonomix Medical from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 3rd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $42.00.

Autonomix Medical Price Performance

Shares of Autonomix Medical stock traded down $0.03 during trading hours on Tuesday, hitting $3.08. The company’s stock had a trading volume of 7,684 shares, compared to its average volume of 1,498,048. The company has a market capitalization of $2.98 million, a PE ratio of -0.07 and a beta of -0.96. The stock has a 50 day moving average of $5.57 and a 200 day moving average of $6.57. Autonomix Medical has a 12 month low of $2.44 and a 12 month high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($5.02) earnings per share for the quarter, beating the consensus estimate of ($6.40) by $1.38. Equities analysts expect that Autonomix Medical will post -20.17 EPS for the current year.

Autonomix Medical Company Profile

Autonomix Medical, Inc is a clinical-stage medical device company developing catheter-based technologies for the diagnosis and treatment of conditions involving the peripheral and autonomic nervous systems. Its platform is designed to help physicians identify and access nerves during minimally invasive procedures.

The company’s technology incorporates a miniature sensor into a catheter to detect neural signals in real time. Autonomix is initially focused on applications in pain management, including procedures intended to treat pain associated with pancreatic cancer, while also evaluating broader uses in chronic pain and other conditions involving abnormal nerve activity.

Autonomix Medical’s products are in the development and clinical-evaluation stages, and the company’s technology may require additional testing, regulatory review and approval before broader commercialization.